Monoclonal Anti‐A from a Hybrid‐Myeloma: Evaluation as a Blood Grouping Reagent
Monoclonal Anti‐A from a Hybrid‐Myeloma: Evaluation as a Blood Grouping Reagent
复制标题
来自混合骨髓瘤的单克隆抗 A：作为血型试剂的评估
作者：
D. Voak;S. Sacks;Thomas Alderson;Fumio Takei;E. Lennox;J. Jarvis;Cesar Milstein;J. Darnborough
单克隆抗 A 抗体经过评估，发现适合用作有效的常规 ABO 分组试剂，无需使用添加剂。 IgM 抗 A (MH2/6D4) 由产生抗 A 的脾细胞和小鼠骨髓瘤细胞系融合衍生的永久克隆细胞系分泌到组织培养上清液中。这是一种具有成本效益的试剂，可降低生产成本 50% 以上。该试剂具有单克隆抗体固有的优点，其中包括可以无限量地获得已知特性的不变抗体。
A monoclonal anti‐A antibody has been evaluated and found suitable for use as a potent routine ABO grouping reagent, without the use of additives. The IgM anti‐A (MH2/6D4) is secreted into the tissue culture supernatant by a permanent line of cloned cells derived by fusion of anti‐A producing spleen cells and a mouse myeloma cell line. This is a costeffective reagent which should reduce production costs by over 50%. This reagent has the advantages inherent in monoclonal antibodies among them the availability of unlimited quantities of unvarying antibody of known properties.